Compassionate Use of Pirtobrutinib for a Patient with Waldenstrom s macroglobulinemia

Go Back to All Clinical Trials

Compassionate Use of Pirtobrutinib for a Patient with Waldenstrom s macroglobulinemia

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Age: Between 18 Year(s) - 100 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. 1. CLL/SLL and have received all 5 classes of available therapy: chemotherapy, anti-cd-20 antibody, covalent Bruton’s Tyrosine Kinase (BTK) inhibitor, BCL-2 inhibitor and PI3K inhibitor;
2. 2. MCL, who has been previously treated with a covalent BTK inhibitor, or Richter’s Transformation, who have had previous Richter’s directed-therapy
3. 3. Waldenstrom macroglobulinemia (WM) patients who were previously treated with chemotherapy, anti-CD20 antibody, and a covalent BTK inhibitor.

You may not be eligible for this study if the following are true:

If you do not meet the inclusion criteria.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies